These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38824414)

  • 61. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
    Lesan V; Olivier T; Prasad V
    Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Outcome switching in randomized controlled oncology trials reporting on surrogate endpoints: a cross-sectional analysis.
    Falk Delgado A; Falk Delgado A
    Sci Rep; 2017 Aug; 7(1):9206. PubMed ID: 28835682
    [TBL] [Abstract][Full Text] [Related]  

  • 64. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
    Sofeu CL; Rondeau V
    PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The area between the curves gets no respect: is it because of the median madness?
    Ajani JA
    J Clin Oncol; 2007 Dec; 25(34):5531. PubMed ID: 18048834
    [No Abstract]   [Full Text] [Related]  

  • 66. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adverse event reporting in cancer clinical trial publications.
    Sivendran S; Latif A; McBride RB; Stensland KD; Wisnivesky J; Haines L; Oh WK; Galsky MD
    J Clin Oncol; 2014 Jan; 32(2):83-9. PubMed ID: 24323037
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
    Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
    J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.
    Huang B; Tian L; Talukder E; Rothenberg M; Kim DH; Wei LJ
    JAMA Oncol; 2018 Jun; 4(6):874-876. PubMed ID: 29710201
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Formal statistical testing and inference in randomized phase II trials in medical oncology.
    Saad ED; Sasse EC; Borghesi G; Miranda VC; Fede AB; Saad LS; Oliveira V; Barros EA; Pascoin M; Del Giglio A; Riechelmann R
    Am J Clin Oncol; 2013 Apr; 36(2):143-5. PubMed ID: 22307212
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.
    Asleh K; Lyck Carstensen S; Tykjaer Jørgensen CL; Burugu S; Gao D; Won JR; Jensen MB; Balslev E; Laenkholm AV; Nielsen DL; Ejlertsen B; Nielsen TO
    Int J Cancer; 2019 May; 144(10):2578-2586. PubMed ID: 30411790
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improved endpoints for cancer immunotherapy trials.
    Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
    J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
    Chen TT
    BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research.
    Sherry AD; Corrigan KL; Kouzy R; Jaoude JA; Yang Y; Patel RR; Totten DJ; Newman NB; Das P; Taniguchi C; Minsky B; Snyder RA; Fuller CD; Ludmir E
    Cancer; 2023 Nov; 129(21):3430-3438. PubMed ID: 37382235
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.
    Wilson MK; Friedlander ML; Joly F; Oza AM
    Oncologist; 2018 Feb; 23(2):203-213. PubMed ID: 29118265
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Endpoints in paediatric oncology.
    Paolucci P; Cioni V; Bigi E; Lucaccioni L; Cano C
    Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():33-40. PubMed ID: 21085937
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
    Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
    Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Kantarjian H; O'Brien S; Jabbour E; Shan J; Ravandi F; Kadia T; Faderl S; Garcia-Manero G; Borthakur G; Cortes J
    J Clin Oncol; 2011 Aug; 29(23):3173-8. PubMed ID: 21747082
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Validation of surrogate endpoints in digestive oncology].
    Methy N; Bedenne L; Bonnetain F
    Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.